Publications, Pharmaceutical

Developing in vitro dissolution tests for orally inhaled drug products

The fate of inhaled drug substances, in vivo, is not well-understood but is believed to be dependent, to some extent, on dissolution characteristics.

This paper presents work to develop an in vitro apparatus and standardized methodology for quantifying the dissolution behavior of orally inhaled drug products. The developed solution incorporates an aerosol dose collection apparatus that collects the dose over a large area, and a modified USP Apparatus V Paddle Over Disc for dissolution testing. The discriminating ability of this solution was demonstrated via testing with a range of commercially available orally inhaled drug products (MDIs and DPIs). Good correlation was observed between in vivo mean absorption time and in vitro dissolution half-life. It is concluded that the developed solution has potential for compendial and QC testing and in the development of both branded and generic orally inhaled drug products.

Download Publication
10 Jun 2020

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

9 Sep 2021

Aptar Pharma talks targeted drug delivery to the upper airways

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
1 Jul 2021

Moving Toward a More Sustainable Future With pMDIs

Publications, Pharmaceutical, Sustainability, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
1 Jul 2021

Using digital therapeutics to improve inhaler use and patient outcomes

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
2 Jun 2021

Aptar Pharma discusses how digital solutions improve patient outcomes

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Read More
1 9 10 11 12 13 19
Back To Top